Replimune Announces Favorable Outcome Of FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Meeting For Rp1 In Advanced Melanoma
REPL•FDA advisory committee gives favorable outcome for Rp1
July 30 (Reuters) - Replimune Group Inc REPL.O:
- Replimune announces favorable outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee meeting for Rp1 in advanced melanoma
- Replimune Group - FDA target action date for Rp1 BLA resubmission is August 2, 2026
